Neal S. Kleiman

Q: What Schools Are Affiliated With Neal S. Kleiman

Neal S. Kleiman is affiliated with the following schools: Baylor College of Medicine, Johns Hopkins University, University of Toronto, Baylor University, New York University, Duke University, Rice University, Brown University, University of Kentucky, Stony Brook University, University of Sydney, University of Alberta, University of Florida, Icahn School of Medicine at Mount Sinai

Neal S. Kleiman's AcademicInfluence.com Rankings

Neal S. Kleiman

Philosophy

#5563

World Rank

#8398

Historical Rank

Logic

#2820

World Rank

#3876

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Neal S. Kleiman Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Neal S. Kleiman's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Transcatheter aortic-valve replacement with a self-expanding prosthesis. (2014) (2348)
Surgical or Transcatheter Aortic‐Valve Replacement in Intermediate‐Risk Patients (2017) (1992)
Transcatheter Aortic‐Valve Replacement with a Self‐Expanding Valve in Low‐Risk Patients (2019) (1873)
Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. (2003) (1177)
Transcatheter aortic valve replacement using a self-expanding bioprosthesis in patients with severe aortic stenosis at extreme risk for surgery. (2014) (909)
Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. (2004) (833)
Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. (1999) (709)
Pharmacological Treatment of Coronary Artery Disease With Recombinant Fibroblast Growth Factor-2: Double-Blind, Randomized, Controlled Clinical Trial (2002) (672)
Cardiac Troponin T Levels for Risk Stratification in Acute Myocardial Ischemia (1996) (671)
Risk factors, angiographic patterns, and outcomes in patients with ventricular septal defect complicating acute myocardial infarction. GUSTO-I (Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries) Trial Investigators. (2000) (630)
A Prospective, Randomized Clinical Trial of Hemodynamic Support With Impella 2.5 Versus Intra-Aortic Balloon Pump in Patients Undergoing High-Risk Percutaneous Coronary Intervention: The PROTECT II Study (2012) (606)
Intravenous platelet blockade with cangrelor during PCI. (2009) (590)
Myonecrosis after revascularization procedures. (1998) (572)
Platelet inhibition with cangrelor in patients undergoing PCI. (2009) (571)
Dobutamine echocardiography in myocardial hibernation. Optimal dose and accuracy in predicting recovery of ventricular function after coronary angioplasty. (1995) (543)
Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. (2006) (494)
Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. (2001) (481)
Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. (1994) (440)
Platelet Glycoprotein IIb/IIIa Inhibitors Reduce Mortality in Diabetic Patients With Non–ST-Segment-Elevation Acute Coronary Syndromes (2001) (429)
Utilization of Early Invasive Management Strategies for High-Risk Patients With Non–ST-Segment Elevation Acute Coronary Syndromes: Results From the CRUSADE Quality Improvement Initiative (2004) (427)
A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. Heparin-Aspirin Reperfusion Trial (HART) Investigators. (1990) (423)
Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. (2004) (418)
Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. (1999) (399)
Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators. (1997) (387)
2-Year Outcomes in Patients Undergoing Surgical or Self-Expanding Transcatheter Aortic Valve Replacement. (2015) (386)
Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I trial experience. The GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. (1995) (376)
Influence of race, sex, and age on management of unstable angina and non-Q-wave myocardial infarction: The TIMI III registry. (1996) (369)
Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. (2007) (361)
International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina (1998) (351)
Long-term Protection From Myocardial Ischemic Events in a Randomized Trial of Brief Integrin β3 Blockade With Percutaneous Coronary Intervention (1997) (347)
Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial (1999) (330)
Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study. (1993) (321)
Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. (2008) (319)
Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study (2001) (318)
Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy. (1999) (314)
Age and outcome with contemporary thrombolytic therapy. Results from the GUSTO-I trial. Global Utilization of Streptokinase and TPA for Occluded coronary arteries trial. (1996) (300)
3-Year Outcomes in High-Risk Patients Who Underwent Surgical or Transcatheter Aortic Valve Replacement. (2016) (286)
Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. (2005) (282)
Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators. (1996) (280)
A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. (2003) (272)
Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Platelet Integrin Glycoprotein IIb/IIIa Blocker Integrelin in Elective Coronary Intervention (1995) (271)
A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. (1994) (264)
Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. (1997) (255)
Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial (2000) (252)
Platelet glycoprotein IIb/IIIa antagonists. What are the relevant issues concerning their pharmacology and clinical use? (1999) (245)
Reticulated platelets and uninhibited COX‐1 and COX‐2 decrease the antiplatelet effects of aspirin (2007) (238)
Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy. (1998) (237)
Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial). (2004) (233)
Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. (1995) (219)
Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. (1996) (217)
Estimation of left ventricular end-diastolic pressure from Doppler transmitral flow velocity in cardiac patients independent of systolic performance. (1992) (216)
First-in-Human Experience of an Antidote-Controlled Anticoagulant Using RNA Aptamer Technology: A Phase 1a Pharmacodynamic Evaluation of a Drug-Antidote Pair for the Controlled Regulation of Factor IXa Activity (2006) (206)
Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Compl (1997) (204)
Coronary angioplasty, atherectomy and bypass surgery in cardiac transplant recipients. (1995) (200)
Mechanical complications after percutaneous coronary intervention in ST-elevation myocardial infarction (from APEX-AMI). (2010) (189)
Early Experience With New Transcatheter Mitral Valve Replacement. (2018) (188)
Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET). (2002) (183)
Intracoronary KAI-9803 as an Adjunct to Primary Percutaneous Coronary Intervention for Acute ST-Segment Elevation Myocardial Infarction (2008) (182)
Prevalence, predictors, and outcomes of patients with non-ST-segment elevation myocardial infarction and insignificant coronary artery disease: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines (CR (2006) (175)
Recombinant hirudin for unstable angina pectoris. A multicenter, randomized angiographic trial. (1994) (168)
Soluble CD40 ligand in acute coronary syndromes. (2003) (166)
Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors. (1995) (163)
Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. (1999) (162)
In-hospital and 1-year outcomes among percutaneous coronary intervention patients with chronic kidney disease in the era of drug-eluting stents: a report from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry. (2009) (161)
Genetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP IIIa and response to aspirin and clopidogrel. (2007) (156)
Combining antiplatelet and anticoagulant therapies. (2009) (156)
Prevention of contrast induced nephropathy: Recommendations for the high risk patient undergoing cardiovascular procedures (2007) (156)
Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience. (1999) (154)
Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Gradient of benefit related to the revascularization strategy. (2002) (152)
Frequency of major noncardiac surgery and subsequent adverse events in the year after drug-eluting stent placement results from the EVENT (Evaluation of Drug-Eluting Stents and Ischemic Events) Registry. (2010) (151)
Bivalirudin and Provisional Glycoprotein IIb/IIIa Blockade Compared With Heparin and Planned Glycoprotein IIb/IIIa Blockade During Percutaneous Coronary Intervention (2003) (150)
Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes. (2009) (150)
Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization. (2002) (145)
Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology. EPIC and EPILOG Investigators. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation of PTCA To Improve Long-term Outcome with abciximab GPIIb/IIIa Receptor Block (1998) (143)
Clinical benefit of glycoprotein IIb/IIIa blockade with Abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome (2000) (142)
Mortality Within 24 Hours of Thrombolysis for Myocardial Infarction: The Importance of Early Reperfusion (1994) (139)
Abciximab Readministration: Results of the ReoPro Readministration Registry (2001) (138)
Percutaneous placement of an intra-aortic balloon pump in the left axillary/subclavian position provides safe, ambulatory long-term support as bridge to heart transplantation. (2013) (136)
Early Outcomes With the Evolut PRO Repositionable Self-Expanding Transcatheter Aortic Valve With Pericardial Wrap. (2018) (135)
Role of myocardial contrast echocardiography during nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. (1998) (134)
Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. (2002) (132)
Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG Investigators. (1997) (131)
Self-Expanding Transcatheter Aortic Valve Replacement or Surgical Valve Replacement in High-Risk Patients 5-Year Outcomes (2018) (130)
Real‐world use of the Impella 2.5 circulatory support system in complex high‐risk percutaneous coronary intervention: The USpella Registry (2012) (129)
Phase 1b Randomized Study of Antidote-Controlled Modulation of Factor IXa Activity in Patients With Stable Coronary Artery Disease (2008) (129)
Intensive medical therapy versus coronary angioplasty for suppression of myocardial ischemia in survivors of acute myocardial infarction: a prospective, randomized pilot study. (1998) (126)
Effect of Mechanically Expanded vs Self-Expanding Transcatheter Aortic Valve Replacement on Mortality and Major Adverse Clinical Events in High-Risk Patients With Aortic Stenosis: The REPRISE III Randomized Clinical Trial (2018) (124)
Assessment, mechanisms, and clinical implication of variability in platelet response to aspirin and clopidogrel therapy. (2009) (123)
Bleeding complications in patients with acute coronary syndrome undergoing early invasive management can be reduced with radial access, smaller sheath sizes, and timely sheath removal (2007) (121)
Circadian variation in the onset of unstable angina and non-Q-wave acute myocardial infarction (the TIMI III Registry and TIMI IIIB). (1997) (121)
Earlier diagnosis and treatment of acute myocardial infarction necessitates the need for a 'new diagnostic mind-set'. (1994) (119)
5-Year Outcomes of Self-Expanding Transcatheter Versus Surgical Aortic Valve Replacement in High-Risk Patients. (2018) (118)
Association of immature platelets with adverse cardiovascular outcomes. (2014) (117)
Platelet activation patterns in platelet size sub-populations: differential responses to aspirin in vitro (2010) (113)
Impact of preprocedural white blood cell count on long term mortality after percutaneous coronary intervention: insights from the EPIC, EPILOG, and EPISTENT trials (2003) (113)
Bioresorbable Scaffold: The Emerging Reality and Future Directions (2017) (112)
Troponin criteria for myocardial infarction after percutaneous coronary intervention. (2012) (109)
Comparison of quantitative coronary angiography to visual estimates of lesion severity pre and post PTCA. (1990) (108)
Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators. (1998) (107)
Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. PURSUIT Investigators. (2000) (104)
Angiotensin-I converting enzyme genotype DD is a risk factor for coronary artery disease. (1995) (99)
Clinical features and pathogenesis of intracerebral hemorrhage after rt-PA and heparin therapy for acute myocardial infarction (1995) (99)
Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. (2008) (98)
1-Year Results in Patients Undergoing Transcatheter Aortic Valve Replacement With Failed Surgical Bioprostheses. (2017) (98)
Diagnosis of ischemic heart disease with adenosine echocardiography. (1991) (98)
Prosthesis-patient mismatch in high-risk patients with severe aortic stenosis: A randomized trial of a self-expanding prosthesis. (2016) (98)
Pharmacodynamics and Pharmacokinetics of Higher-Dose, Double-Bolus Eptifibatide in Percutaneous Coronary Intervention (2001) (96)
Effect of Catheter Ablation With Vein of Marshall Ethanol Infusion vs Catheter Ablation Alone on Persistent Atrial Fibrillation: The VENUS Randomized Clinical Trial. (2020) (95)
Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet Glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: results of a multicenter, placebo-controlled, randomized trial. (1998) (94)
Arrhythmic Burden as Determined by Ambulatory Continuous Cardiac Monitoring in Patients With New-Onset Persistent Left Bundle Branch Block Following Transcatheter Aortic Valve Replacement: The MARE Study. (2018) (94)
Shear-induced platelet aggregation is inhibited by in vivo infusion of an anti-glycoprotein IIb/IIIa antibody fragment, c7E3 Fab, in patients undergoing coronary angioplasty. (1995) (94)
Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibi (2006) (89)
Results from late-breaking clinical trials sessions at ACCIS 2000 and ACC 2000. American College of Cardiology. (2000) (89)
Prognostic impact of periprocedural bleeding and myocardial infarction after percutaneous coronary intervention in unselected patients: results from the EVENT (evaluation of drug-eluting stents and ischemic events) registry. (2009) (89)
Comparative real-time effects on platelet adhesion and aggregation under flowing conditions of in vivo aspirin, heparin, and monoclonal antibody fragment against glycoprotein IIb-IIIa. (1995) (88)
Potential role of activated platelets in homing of human endothelial progenitor cells to subendothelial matrix (2006) (88)
Predicting Restenosis of Drug-Eluting Stents Placed in Real-World Clinical Practice: Derivation and Validation of a Risk Model From the EVENT Registry (2010) (87)
Dalteparin in combination with abciximab during percutaneous coronary intervention. (2001) (87)
Chimeric 7E3 Fab (ReoPro) decreases detectable CD11b on neutrophils from patients undergoing coronary angioplasty. (1999) (83)
Disagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT study (2001) (82)
Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: results of the PROTECTION AMI Randomized Controlled Trial. (2014) (81)
Association Between Transcatheter Aortic Valve Replacement and Early Postprocedural Stroke. (2019) (81)
Results from a phase II multicenter, double-blind placebo-controlled study of Del-1 (VLTS-589) for intermittent claudication in subjects with peripheral arterial disease. (2007) (81)
Comparison by meta-analysis of mortality after isolated coronary artery bypass grafting in women versus men. (2013) (80)
Effectiveness of early coronary angioplasty and abciximab for failed thrombolysis (reteplase or alteplase) during acute myocardial infarction (results from the GUSTO-III trial). Global Use of Strategies To Open occluded coronary arteries. (1999) (80)
Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial (vol 292, pg 696, 2004) (2006) (80)
Effect of P-Selectin on Phosphatidylserine Exposure and Surface-Dependent Thrombin Generation on Monocytes (2005) (79)
Heparin-induced prolongation of partial thromboplastin time after thrombolysis: relation to coronary artery patency. HART Investigators. (1992) (78)
Regression of Paravalvular Aortic Regurgitation and Remodeling of Self-Expanding Transcatheter Aortic Valve: An Observation From the CoreValve U.S. Pivotal Trial. (2015) (78)
Neurological Events Following Transcatheter Aortic Valve Replacement and Their Predictors: A Report From the CoreValve Trials (2016) (77)
Management of Patients With Acute Coronary Syndromes in the United States by Platelet Glycoprotein IIb/IIIa Inhibition: Insights From the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial (2000) (76)
Treatment of aspirin-resistant patients with omega-3 fatty acids versus aspirin dose escalation. (2010) (76)
Long-Term Outcomes With Transcatheter Aortic Valve Replacement in Women Compared With Men: Evidence From a Meta-Analysis. (2017) (76)
High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: results from TIMI (thrombolysis in myocardial infarction) 14. (2000) (76)
Intravenous recombinant tissue-type plasminogen activator in patients with unstable angina pectoris. Results of a placebo-controlled, randomized trial. (1990) (76)
Pharmacokinetics and pharmacodynamics of glycoprotein IIb-IIIa inhibitors. (1999) (74)
Health status after transcatheter aortic valve replacement in patients at extreme surgical risk: results from the CoreValve U.S. trial. (2015) (73)
Angiogenic gene therapy with adenovirus 5 fibroblast growth factor-4 (Ad5FGF-4): a new option for the treatment of coronary artery disease. (2003) (73)
First Experience With Direct Factor Xa Inhibition in Patients With Stable Coronary Disease: A Pharmacokinetic and Pharmacodynamic Evaluation (2002) (72)
Percutaneous transluminal coronary angioplasty in octogenarians. (1990) (72)
Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study). (2001) (71)
Triage Considerations for Patients Referred for Structural Heart Disease Intervention During the Coronavirus Disease 2019 (COVID-19) Pandemic: An ACC /SCAI Consensus Statement (2020) (71)
Systematic adjudication of myocardial infarction end-points in an international clinical trial (2001) (70)
High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trial. (2005) (69)
Outcomes in the Randomized CoreValve US Pivotal High Risk Trial in Patients With a Society of Thoracic Surgeons Risk Score of 7% or Less. (2016) (68)
Self-expanding transcatheter aortic valve replacement using alternative access sites in symptomatic patients with severe aortic stenosis deemed extreme risk of surgery. (2014) (67)
Sustained platelet glycoprotein IIb/IIIa blockade with oral xemilofiban in 170 patients after coronary stent deployment. (1997) (67)
Association Between Hospital Volume and 30-Day Readmissions Following Transcatheter Aortic Valve Replacement (2017) (67)
Argatroban Anticoagulation in Conjunction with Glycoprotein IIb/IIIa Inhibition in Patients Undergoing Percutaneous Coronary Intervention: An Open-Label, Nonrandomized Pilot Study (2004) (66)
Prevalence and Prognostic Significance of Preprocedural Cardiac Troponin Elevation Among Patients With Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: Results From the Evaluation of Drug Eluting Stents and Ischemic Events Registry (2008) (66)
Two- and three-year results of the thrombolysis in myocardial infraction (TIMI) phaes II clinical trial (1993) (65)
Initial experience with a magnetic navigation system for percutaneous coronary intervention in complex coronary artery lesions. (2006) (65)
Differential dose-response to oral xemilofiban after antecedent intravenous abciximab. Administration for complex coronary intervention. (1996) (65)
Effect of nitric oxide synthase inhibition on haemodynamics and outcome of patients with persistent cardiogenic shock complicating acute myocardial infarction: a phase II dose-ranging study. (2007) (65)
Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. Second Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network Trial. (2002) (64)
Prinzmetal's angina during 5-fluorouracil chemotherapy. (1987) (64)
Low-molecular-weight heparin therapy for non-ST-elevation acute coronary syndromes and during percutaneous coronary intervention: an expert consensus. (2002) (64)
Enhanced Efficacy of Eptifibatide Administration in Patients With Acute Coronary Syndrome Requiring In-Hospital Coronary Artery Bypass Grafting (2000) (63)
Platelet reactivity and response to aspirin in subjects with the metabolic syndrome. (2008) (61)
Is glycoprotein IIb/IIIa antagonism as effective in women as in men following percutaneous coronary intervention?. Lessons from the ESPRIT study. (2002) (60)
Relation of left ventricular dilation during acute myocardial infarction to systolic performance, diastolic dysfunction, infarct size and location. (1988) (60)
Coronary flow reserve may predict myocardial recovery after myocardial infarction in patients with TIMI grade 3 flow. (1998) (59)
Pharmacodynamics and Pharmacokinetics of Eptifibatide in Patients With Acute Coronary Syndromes: Prospective Analysis From PURSUIT (2001) (59)
Impact of Age on Clinical Outcome and Postlytic Management Strategies in Patients Treated With Intravenous Thrombolytic Therapy: Results From the TIMI II Study (1994) (59)
2-Year Outcomes After Iliofemoral Self-Expanding Transcatheter Aortic Valve Replacement in Patients With Severe Aortic Stenosis Deemed Extreme Risk for Surgery. (2015) (58)
Long‐Term Protection from Myocardial Ischemic Events in a Randomized Trial of Brief Integrin β3 Blockade with Percutaneous Coronary Intervention (1998) (58)
Time to Coronary Angiography and Outcomes Among Patients With High-Risk Non–ST-Segment–Elevation Acute Coronary Syndromes: Results From the SYNERGY Trial (2007) (57)
Trends and Outcomes of Off-label Use of Transcatheter Aortic Valve Replacement: Insights From the NCDR STS/ACC TVT Registry (2017) (57)
Platelet glycoprotein IIIa PlA polymorphism and myocardial infarction. (1996) (57)
One-year outcomes of patients with severe aortic stenosis and an STS PROM of less than three percent in the SURTAVI trial. (2018) (57)
Confronting the issues of patient safety and investigator conflict of interest in an international clinical trial of myocardial reperfusion. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) Steering Committee. (1992) (57)
Prospective analysis of creatine kinase muscle-brain fraction and comparison with troponin T to predict cardiac risk and benefit of an invasive strategy in patients with non-ST-elevation acute coronary syndromes. (2002) (56)
Bioprosthetic Aortic Valve Leaflet Thickening in the Evolut Low Risk Sub-Study (2020) (56)
Circulating Endothelial Progenitor Cells and Coronary Collaterals in Patients with Non-ST Segment Elevation Myocardial Infarction (2005) (55)
Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb/IIIa receptor blocker. (2002) (55)
First experience with direct, selective factor Xa inhibition in patients with non‐ST‐elevation acute coronary syndromes: results of the XaNADU‐ACS Trial (2005) (55)
Immature platelet fraction (IPF) determined with an automated method predicts clopidogrel hyporesponsiveness (2012) (55)
Repeat Revascularization After Contemporary Percutaneous Coronary Intervention: An Evaluation of Staged, Target Lesion, and Other Unplanned Revascularization Procedures During the First Year (2012) (54)
Prediction of One-Year Survival in High-Risk Patients with Acute Coronary Syndromes: Results from the SYNERGY Trial (2008) (53)
Dynamic prognostication in non-ST-elevation acute coronary syndromes: insights from GUSTO-IIb and PURSUIT. (2004) (53)
Comparison of outcome of patients with unstable angina and non-Q-wave acute myocardial infarction with and without prior coronary artery bypass grafting (Thrombolysis in Myocardial Ischemia III Registry). (1996) (52)
Temporal trends in the use of early cardiac catheterization in patients with non-ST-segment elevation acute coronary syndromes (results from CRUSADE). (2006) (52)
Double jeopardy of renal insufficiency and anemia in patients undergoing percutaneous coronary interventions. (2004) (51)
Initial experience with factor‐Xa inhibition in percutaneous coronary intervention: the XaNADU‐PCI Pilot (2004) (51)
Aspirin dose and six-month outcome after an acute coronary syndrome. (2004) (51)
Lack of diurnal variation in the onset of non-Q wave infarction. (1990) (50)
Bringing it all together: integration of physiology with anatomy during cardiac catheterization. (2011) (50)
Prognostic Implications of Creatine Kinase-MB Elevation After Percutaneous Coronary Intervention: Results From the Evaluation of Drug-Eluting Stents and Ischemic Events (EVENT) Registry (2011) (49)
Mechanisms of early death despite thrombolytic therapy: experience from the Thrombolysis in Myocardial Infarction Phase II (TIMI II) study. (1992) (49)
Lack of usefulness of prolonged bleeding times in predicting hemorrhagic events in patients receiving the 7E3 glycoprotein IIb/IIIa platelet antibody. The TAMI Study Group. (1993) (48)
Redefining medical treatment in the management of unstable angina. (2011) (48)
Transcatheter Aortic Valve Replacement in Low-risk Patients With Bicuspid Aortic Valve Stenosis. (2020) (47)
Clinical and Economic Outcomes of Liberal Versus Selective Drug-Eluting Stent Use: Insights From Temporal Analysis of the Multicenter Evaluation of Drug Eluting Stents and Ischemic Events (EVENT) Registry (2011) (47)
Platelet–monocyte complex formation: effect of blocking PSGL-1 alone, and in combination with αIIbβ3 and αMβ2, in coronary stenting (2003) (47)
Temporal Trends and Outcomes of Transcatheter Versus Surgical Aortic Valve Replacement for Bicuspid Aortic Valve Stenosis. (2019) (47)
Simultaneous Modeling of Abciximab Plasma Concentrations and ex Vivo Pharmacodynamics in Patients Undergoing Coronary Angioplasty (2003) (47)
Triage considerations for patients referred for structural heart disease intervention during the COVID‐19 pandemic: An ACC/SCAI position statement (2020) (46)
Does intracoronary thrombus influence the outcome of high risk percutaneous transluminal coronary angioplasty? Clinical and angiographic outcomes in a large multicenter trial. EPIC Investigators. Evaluation of IIb/IIIa Platelet Receptor Antagonist 7E3 in Preventing Ischemic Complications. (1998) (46)
Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab. (2000) (46)
Early Trifecta valve failure: Report of a cluster of cases from a tertiary care referral center (2017) (45)
Evaluation and management of thrombocytopenia and suspected heparin-induced thrombocytopenia in hospitalized patients: The Complications After Thrombocytopenia Caused by Heparin (CATCH) registry. (2009) (44)
Early Recovery of Left Ventricular Systolic Function After CoreValve Transcatheter Aortic Valve Replacement (2016) (44)
Red cell distribution width is a predictor of mortality in patients undergoing percutaneous coronary intervention (2012) (43)
New-Generation Coronary Stents: Current Data and Future Directions (2017) (43)
Effects of low-dose aspirin on in vitro platelet aggregation in the early minutes after ingestion in normal subjects. (1994) (42)
Effects of abciximab, ticlopidine, and combined Abciximab/Ticlopidine therapy on platelet and leukocyte function in patients undergoing coronary angioplasty. (2000) (42)
A novel point-of-care enoxaparin monitor for use during percutaneous coronary intervention. Results of the Evaluating Enoxaparin Clotting Times (ELECT) Study. (2003) (42)
Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT Investigators. (1995) (42)
Use of bivalirudin during percutaneous coronary intervention in patients with diabetes mellitus: an analysis from the randomized evaluation in percutaneous coronary intervention linking angiomax to reduced clinical events (REPLACE)-2 trial. (2005) (41)
Percutaneous coronary intervention vs. coronary artery bypass graft surgery for unprotected left main coronary artery disease in the drug-eluting stents era--an aggregate data meta-analysis of 11,148 patients. (2013) (41)
Cardiogenic shock and heart failure post-percutaneous coronary intervention in ST-elevation myocardial infarction: observations from "Assessment of Pexelizumab in Acute Myocardial Infarction". (2011) (40)
Interobserver variability in grading of coronary arterial narrowings using the American College of Cardiology/American Heart Association grading criteria. (1992) (40)
Comparison of adenosine echocardiography, with and without isometric handgrip, to exercise echocardiography in the detection of ischemia in patients with coronary artery disease. (1996) (39)
The effect of percutaneous coronary intervention on inflammatory response and endothelial progenitor cell recruitment (2008) (39)
Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy. (2004) (39)
Impact of Periprocedural Myocardial Biomarker Elevation on Mortality Following Elective Percutaneous Coronary Intervention. (2019) (39)
Differential Treatment Benefit of Platelet Glycoprotein IIb/IIIa Inhibition With Percutaneous Coronary Intervention Versus Medical Therapy for Acute Coronary Syndromes: Exploration of Methods (2004) (37)
Leaflet Thickening or Immobility Following Aortic Valve Replacement: Results from the Evolut Low Risk Sub-study. (2020) (37)
Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial. (2006) (37)
Relation between inhibition of platelet aggregation and clinical outcomes. (1998) (35)
Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. EPILOG Investigators. Evaluation of PTCA to Improve Long-term Outcome by c7E3 GP IIb/IIIa Receptor Blockade. (1998) (35)
Identification, Diagnosis and Treatment of Heparin-induced Thrombocytopenia and Thrombosis: A Registry of Prolonged Heparin Use and Thrombocytopenia among Hospitalized Patients with and without Cardiovascular Disease (2005) (35)
Natural History of Functional Tricuspid Regurgitation Quantified by Cardiovascular Magnetic Resonance. (2020) (35)
Angiographic adverse events, creatine kinase-MB elevation, and ischemic end points complicating percutaneous coronary intervention (a REPLACE-2 substudy). (2006) (35)
Benefit of early sustained reperfusion in patients with prior myocardial infarction (the GUSTO-I trial). Global Utilization of Streptokinase and TPA for occluded arteries. (1998) (34)
Evolving revascularization approaches for myocardial ischemia. (2003) (34)
Optimizing rotational atherectomy in high‐risk percutaneous coronary interventions: Insights from the PROTECT ΙΙ study (2014) (34)
Red cell distribution width as a bleeding predictor after percutaneous coronary intervention. (2013) (33)
Transcatheter Aortic Valve Replacement Versus Surgery in Women at High Risk for Surgical Aortic Valve Replacement (from the CoreValve US High Risk Pivotal Trial). (2016) (33)
Hemorrhagic events during therapy with recombinant tissue plasminogen activator, heparin, and aspirin for unstable angina (Thrombolysis in Myocardial Ischemia, phase IIIB trial). (1997) (33)
The REPLACE 1 trial: a pilot study of bivalirudin versus heparin during percutaneous coronary intervention with stenting and GP IIb/IIIa blockade (2002) (32)
Asymptomatic Cardiac Ischemia Pilot study (ACIP) (1992) (31)
The risk and extent of neurologic events are equivalent for high-risk patients treated with transcatheter or surgical aortic valve replacement. (2016) (31)
Effects of SolCD39, a Novel Inhibitor of Platelet Aggregation, on Platelet Deposition and Aggregation after PTCA in a Porcine Model (2005) (31)
Hypertrophy Regression With N-Acetylcysteine in Hypertrophic Cardiomyopathy (HALT-HCM): A Randomized, Placebo-Controlled, Double-Blind Pilot Study (2018) (31)
Clinical or Symptomatic Leaflet Thrombosis Following Transcatheter Aortic Valve Replacement: Insights from the U.S. FDA MAUDE Database (2017) (31)
Visualization of ventricular fibroelastoma with a video-assisted thoracoscope. (1997) (31)
Survival Benefit With Drug-Eluting Stents in Observational Studies: Fact or Artifact? (2011) (31)
Design of a registry to characterize "real-world" outcomes of percutaneous coronary revascularization in the drug-eluting stent era. (2005) (30)
Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Prior Coronary Artery Bypass Grafting: Trends in Utilization and Propensity-Matched Analysis of In-Hospital Outcomes (2018) (30)
Magnetic resonance imaging for assessment of tissue rejection after heterotopic heart transplantation. (1993) (30)
Impact of drug eluting stent length on outcomes of percutaneous coronary intervention (from the EVENT registry). (2012) (29)
Prognostic implications of procedural vs spontaneous myocardial infarction: results from the Evaluation of Drug Eluting Stents and Ischemic Events (EVENT) registry. (2013) (29)
Long-term Efficacy of Bivalirudin and Provisional Glycoprotein IIb/IIIa Blockade vs Heparin and Planned Glycoprotein IIb/IIIa Blockade During Percutaneous Coronary Revascularization (2004) (28)
Two- and three-year results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II clinical trial. (1993) (28)
Platelet reactivity in patients with subacute stent thrombosis compared with non-stent-related acute myocardial infarction. (2007) (28)
Pharmacodynamic profile of the direct thrombin antagonist bivalirudin given in combination with the glycoprotein IIb/IIIa antagonist eptifibatide. (2002) (27)
Incidence and Outcomes of Surgical Bailout During TAVR: Insights From the STS/ACC TVT Registry. (2019) (27)
Impact of Annular Size on Outcomes After Surgical or Transcatheter Aortic Valve Replacement. (2018) (27)
Comparison by meta-analysis of percutaneous coronary intervention versus coronary artery bypass grafting in patients with a mean age of ≥70 years. (2013) (27)
Bleeding Risk Comparing Targeted Low-Dose Heparin With Bivalirudin in Patients Undergoing Percutaneous Coronary Intervention: Results From a Propensity Score–Matched Analysis of the Evaluation of Drug-Eluting Stents and Ischemic Events (EVENT) Registry (2011) (26)
Closure devices and vascular complications among percutaneous coronary intervention patients receiving enoxaparin, glycoprotein IIb/IIIa inhibitors, and clopidogrel (2005) (26)
Incidence and clinical outcome of minor surgery in the year after drug-eluting stent implantation: results from the Evaluation of Drug-Eluting Stents and Ischemic Events Registry. (2011) (26)
Evaluation of a New Heparin Agent in Percutaneous Coronary Intervention: Results of the Phase 2 Evaluation of M118 IN pErcutaNeous Coronary intErvention (EMINENCE) Trial (2010) (26)
Heparin versus aspirin after recombinant tissue plasminogen activator therapy in myocardial infarction: A randomized trial (1990) (25)
Increased platelet sensitivity among individuals with aspirin resistance – Platelet aggregation to submaximal concentration of arachidonic acid predicts response to antiplatelet therapy (2008) (25)
Degree of HLA mismatch as a predictor of death from allograft arteriopathy after heart transplant. (1993) (24)
Platelet abnormalities in diabetes mellitus (2003) (24)
Factors determining improvement in left ventricular function after reperfusion therapy for acute myocardial infarction: primacy of baseline ejection fraction. (1991) (24)
Relation of an elevated white blood cell count after percutaneous coronary intervention to long-term mortality. (2004) (24)
Effect of caffeine on platelet inhibition by clopidogrel in healthy subjects and patients with coronary artery disease. (2007) (24)
Early clinical experience with integrelin, an inhibitor of the platelet glycoprotein IIb/IIIa integrin receptor. (1995) (24)
Elevated soluble interleukin-2 receptor levels early after heart transplantation and long-term survival and development of coronary arteriopathy. (1991) (24)
Release kinetics of circulating cardiac myosin binding protein-C following cardiac injury. (2014) (23)
Neurological Complications After Transcatheter Versus Surgical Aortic Valve Replacement in Intermediate-Risk Patients. (2018) (23)
Multicenter, dose-ranging study of efegatran sulfate versus heparin with thrombolysis for acute myocardial infarction: The Promotion of Reperfusion in Myocardial Infarction Evolution (PRIME) trial. (2002) (23)
Effects of Integrelin on platelet function in flow models of arterial thrombosis. (1997) (23)
Pharmacokinetics and Pharmacodynamics of Argatroban in Combination With a Platelet Glycoprotein IIB/IIIA Receptor Antagonist in Patients Undergoing Percutaneous Coronary Intervention (2004) (23)
Pharmacodynamics of abciximab during angioplasty: Comparison to healthy subjects (2002) (23)
Triage Considerations for Patients Referred for Structural Heart Disease Intervention During the COVID-19 Pandemic (2020) (23)
711-3-A Multicenter, Randomized, Double-Blind Pilot Trial of Standard Versus Low Dose Weight-Adjusted Heparin in Patients Treated with the Platelet GP IIb/IIIa Receptor Antibody c7E3 During Percutaneous Coronary Revascularization (1995) (22)
Causes of death from the randomized CoreValve US Pivotal High‐Risk Trial (2017) (22)
Clinical impact of baseline chronic kidney disease in patients undergoing transcatheter or surgical aortic valve replacement (2018) (22)
711-3-A Multicenter, Randomized, Double-Blind Pilot Trial of Standard Versus Low Dose Weight-Adjusted Heparin in Patients Treated with the Platelet GP IIb/IIIa Receptor Antibody c7E3 During Percutaneous Coronary Revascularization (1995) (22)
2-Year Outcomes After Transcatheter Versus Surgical Aortic Valve Replacement in Low-Risk Patients. (2022) (21)
Platelet-monocyte complex formation: effect of blocking PSGL-1 alone, and in combination with alphaIIbbeta3 and alphaMbeta2, in coronary stenting. (2003) (21)
Durability and Clinical Outcomes of Transcatheter Aortic Valve Replacement for Failed Surgical Bioprostheses. (2019) (21)
Detection of transplant arteriopathy: does exercise thallium scintigraphy improve noninvasive diagnostic capabilities? (1991) (21)
Progressive deterioration of coronary flow reserve after heart transplantation. (1998) (21)
Clinical Outcomes of Percutaneous Interventions in Saphenous Vein Grafts Using Drug‐Eluting Stents Compared to Bare‐Metal Stents: A Comprehensive Meta‐Analysisof All Randomized Clinical Trials (2012) (21)
Platelet pathophysiology, pharmacology, and function in coronary artery disease. (2017) (20)
Inability of isolated soluble interleukin-2 receptor levels to predict biopsy rejection scores after heart transplantation. (1991) (20)
Effect of ranitidine on the antiplatelet effects of aspirin in healthy human subjects. (2007) (20)
Incidence, treatment, and outcomes of atrial fibrillation complicating non-ST-segment elevation acute coronary syndromes. (2013) (20)
Detection and quantification of circulating immature platelets: agreement between flow cytometric and automated detection (2016) (20)
Response to aspirin and clopidogrel in patients scheduled to undergo cardiovascular surgery (2007) (19)
Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab thrombolytic therapy (1993) (19)
What are the implications of cardiac infection with cytomegalovirus before heart transplantation? (1994) (19)
Resistance to antiplatelet therapy (2005) (19)
Role of Teleproctoring in Challenging and Innovative Structural Interventions Amid the COVID-19 Pandemic and Beyond (2020) (19)
The relationship of soluble interleukin-2 receptor levels to allograft arteriopathy after heart transplantation. (1992) (19)
Abciximab, ticlopidine, and concomitant abciximab-ticlopidine therapy: ex vivo platelet aggregation inhibition profiles in patients undergoing percutaneous coronary interventions. (2000) (18)
Anti-thrombotic effect of bivalirudin compared with eptifibatide and unfractionated heparin in diabetic patients (2006) (18)
Pharmacology of the intravenous platelet receptor glycoprotein IIb-IIIa antagonists. (1998) (18)
Early intravenous thrombolytic therapy for acute myocardial infarction in patients with prior coronary artery bypass grafts. (1989) (18)
Aortic Valve Replacement in Bioprosthetic Failure:Insights from The Society of Thoracic Surgeons National Database. (2020) (18)
Does Intracoronary Thrombus Influence the Outcome of High Risk Percutaneous Transluminal Coronary Angioplasty? Clinical and Angiographic Outcomes in a Large Multicenter Trial fn1fn1This study was suppported by a grant from Centocor, Inc. (1998) (17)
Enoxaparin 0.3 mg/kg IV supplement for patients transitioning to PCI after subcutaneous enoxaparin therapy for NSTE ACS: A subgroup analysis from the SYNERGY trial (2010) (17)
Acute myocardial infarction and cardiac arrest in a patient receiving paclitaxel. (2003) (17)
Stent-assisted coil embolization of a large fusiform aneurysm of proximal anterior descending artery: novel treatment for coronary aneurysms. (2012) (17)
Phase 1 b Randomized Study of Antidote-Controlled Modulation of Factor IXa Activity in Patients With Stable Coronary Artery Disease (2008) (17)
Provisional glycoprotein IIb/IIIa blockade in a randomized investigation of bivalirudin versus heparin plus planned glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: predictors and outcome in the Randomized Evaluation in Percutaneous coronary intervention Linking Angiomax t (2006) (17)
Platelets: Developmental biology, physiology, and translatable platforms for preclinical investigation and drug development (2008) (17)
Vein of Marshall ethanol infusion for persistent atrial fibrillation: VENUS and MARS clinical trial design. (2019) (17)
Direct Aortic Access for Transcatheter Aortic Valve Replacement Using a Self-Expanding Device. (2017) (17)
Prognostic significance of bleeding location and severity among patients with acute coronary syndromes. (2013) (17)
Telerobotic stroke intervention: a novel solution to the care dissemination dilemma. (2019) (17)
Primary and secondary safety endpoints from IMPACT II (1997) (16)
The declining prevalence of ST elevation myocardial infarction in patients presenting with acute coronary syndromes (2005) (16)
Direct aortic and subclavian access for transcatheter aortic valve replacement: decision making and technique. (2014) (16)
Effects of intracoronary acetylcholine infusion early versus late after heart transplant. (1991) (15)
Propensity-Matched 1-Year Outcomes Following Transcatheter Aortic Valve Replacement in Low-Risk Bicuspid and Tricuspid Patients. (2022) (15)
Multivessel drug‐eluting stenting and impact of diabetes mellitus—A report from the EVENT registry (2009) (15)
Accreditation and funding for a 24‐month advanced interventional cardiology fellowship program: A call‐to‐action for optimal training of the next generation of interventionalists (2016) (15)
Intravenous adenosine echocardiography, a new pharmacologic stress test: Preliminary results and comparison with simultaneous thallium scintigraphy (1990) (15)
The safety of clopidogrel (2011) (15)
Determinants of outcome impact of Vein of Marshall Ethanol infusion when added to catheter ablation of persistent atrial fibrillation: A secondary analysis of the VENUS randomized clinical trial. (2021) (15)
Inhibition of coronary restenosis by antithrombin III in atherosclerotic swine (1996) (14)
Will measuring vasodilator-stimulated phosphoprotein phosphorylation help us optimize the loading dose of clopidogrel? (2008) (14)
Heparin Monotherapy or Bivalirudin During Percutaneous Coronary Intervention in Patients With Non–ST-Segment–Elevation Acute Coronary Syndromes or Stable Ischemic Heart Disease: Results From the Evaluation of Drug-Eluting Stents and Ischemic Events Registry (2014) (14)
Grabbing the horns of a dilemma: the duration of dual antiplatelet therapy after stent implantation. (2012) (14)
Reticulated Platelets: Changing Focus from Basics to Outcomes (2018) (13)
Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways (2012) (13)
A comparison of ionic versus nonionic contrast medium during primary percutaneous transluminal coronary angioplasty for acute myocardial infarction (GUSTO IIb). Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes. (2000) (13)
Delaying and Preventing Ischemic Events in Patients with Acute Coronary Syndromes Using the Platelet Glycoprotein IIb/IIIa Inhibitor Lamifiban (1997) (13)
TCT-743 Percutaneous Coronary Intervention after Self-Expanding Transcatheter Aortic Valve Replacement. (2016) (13)
Inhibition of Platelet Aggregation with a Glycoprotein IIb-IIIa Antagonist Does Not Prevent Thrombin Generation in Patients Undergoing Thrombolysis for Acute Myocardial Infarction (2004) (13)
Regional Variation in Utilization, In-hospital Mortality, and Health-Care Resource Use of Transcatheter Aortic Valve Implantation in the United States. (2017) (13)
Therapeutic Use of Intravenous Eptifibatide in Patients Undergoing Percutaneous Coronary Intervention (2004) (12)
Rapid adoption of drug-eluting stents: clinical practices and outcomes from the early drug-eluting stent era. (2010) (12)
Is intravascular ultrasound better than quantitative coronary arteriography to assess cardiac allograft arteriopathy? (1994) (12)
Prescription Patterns of Clopidogrel, Prasugrel, and Ticagrelor After Percutaneous Coronary Intervention With Stent Implantation (from the NCDR PINNACLE Registry). (2019) (12)
Comparison of the use of hemodynamic support in patients ≥80 years versus patients <80 years during high-risk percutaneous coronary interventions (from the Multicenter PROTECT II Randomized Study). (2014) (12)
In-hospital and 1-year outcomes among unselected percutaneous coronary intervention patients treated with either sirolimus- or paclitaxel-eluting stents: results from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry. (2009) (12)
Percutaneous coronary high speed rotational atherectomy new but how safe (1990) (12)
Strategic lessons from the clinical event classification process for the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. (2011) (12)
Advances in Transcatheter Aortic Valve Replacement. (2016) (12)
Arterial thrombosis for the interventional cardiologist: From adhesion molecules and coagulation factors to clinical therapeutics (2003) (12)
Renin‐Angiotensin System Blockade in Aortic Stenosis: Implications Before and After Aortic Valve Replacement (2020) (12)
Statin therapy in patients with chronic kidney disease undergoing percutaneous coronary intervention (from the Evaluation of Drug Eluting Stents and Ischemic Events Registry). (2014) (12)
Platelet reactivity among Asian Indians and Caucasians (2007) (12)
Mode of death after contemporary percutaneous coronary intervention: a report from the Evaluation of Drug Eluting Stents and Ischemic Events registry. (2011) (12)
Mechanical Circulatory Support in High-Risk Percutaneous Coronary Intervention. (2018) (12)
GP IIb/IIIa Antagonists (1999) (12)
Coronary angiography after heart transplantation: should perioperative study be the "gold standard"? (1992) (11)
Platelets and platelet inhibitors in acute myocardial infarction. (1995) (11)
Tip-to-Base LAMPOON for Transcatheter Mitral Valve Replacement With a Protected Mitral Annulus. (2021) (11)
Direct Aortic Access Transcatheter Aortic Valve Replacement: Three-Dimensional Computed Tomography Planning and Real-Time Fluoroscopic Image Guidance. (2015) (11)
Putting heparin into perspective: its history and the evolution of its use during percutaneous coronary interventions. (2000) (11)
Derivation and external validation of a simple risk tool to predict 30-day hospital readmissions after transcatheter aortic valve replacement. (2019) (11)
Determinants of plasma vitamin D levels in patients with acute coronary syndromes (2011) (11)
Acute myocardial infarction: clinical characteristics, management and outcome in a university medical centre in a developing Middle Eastern country. (2004) (11)
Low-dose sirolimus-eluting hydroxyapatite coating on stents does not increase platelet activation and adhesion ex vivo (2012) (11)
Therapeutic strategies for cardiogenic shock, 2006 (2006) (11)
Late Electrocardiographic Changes in Patients With New-Onset Left Bundle Branch Block Following Transcatheter Aortic Valve Implantation. (2019) (11)
Arrhythmic burden in patients with new-onset persistent left bundle branch block after transcatheter aortic valve replacement: 2-year results of the MARE study. (2020) (11)
Patterns of activation and deposition of platelets exposed to the polymeric surface of the paclitaxel eluting stent (2009) (11)
Vascular complication can be minimized with a balloon‐expandable, re‐collapsible sheath in TAVR with a self‐expanding bioprosthesis (2016) (11)
Death and nonfatal reinfarction within the first 24 hours after presentation with an acute coronary syndrome: experience from GUSTO-IIb. Global Utilization of Strategies for Total Occlusion. (1999) (11)
Rotational ablation of coronary artery lesions using single, large burrs. (1992) (10)
Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: pathophysiologic foundation and clinical findings. (1998) (10)
Complete 2-Year Results Confirm Bayesian Analysis of the SURTAVI Trial. (2020) (10)
Measuring troponin elevation after percutaneous coronary intervention: ready for prime time? (2006) (10)
Stenting of a left main coronary artery compressed by a dilated main pulmonary artery (2013) (10)
Room considerations with TAVR. (2012) (10)
Prognostic Value of Computed Tomography-Derived Fractional Flow Reserve Comparison With Myocardial Perfusion Imaging. (2021) (9)
Platelets, the cardiologist, and coronary artery disease: moving beyond aggregation. (2004) (9)
One-Year Outcomes of Transcatheter Aortic Valve Replacement in Patients With End-Stage Renal Disease. (2017) (9)
Initial experience with alcohol septal ablation using a novel magnetic navigation system. (2007) (9)
Hypertrophic obstructive cardiomyopathy: Alternative therapeutic options (1997) (9)
The Implications of Acute Clinical Care Responsibilities on the Contemporary Practice of Interventional Cardiology. (2019) (9)
Relation of coagulation parameters to patency and recurrent ischemia in the Thrombolysis in Myocardial Infarction (TIMI) Phase II Trial. (1998) (8)
Subclinical Leaflet Thrombosis and Clinical Outcomes after TAVR: A Systematic Review and Meta-Analysis (2018) (8)
Transcatheter aortic valve replacement in patients with severe mitral or tricuspid regurgitation at extreme risk for surgery (2018) (8)
Self-expanding Transcatheter vs Surgical Aortic Valve Replacement in Intermediate-Risk Patients: 5-Year Outcomes of the SURTAVI Randomized Clinical Trial. (2022) (8)
Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY Library. (2004) (8)
Effect of increasing age on percutaneous coronary intervention vs coronary artery bypass grafting in older adults with unprotected left main coronary artery disease: A meta‐analysis and meta‐regression (2019) (8)
Impact of Myocardial Scar on Prognostic Implication of Secondary Mitral Regurgitation in Heart Failure. (2020) (8)
Abciximab Pharmacodynamic Model with Neural Networks used to Integrate Sources of Patient Variability (2004) (8)
Simultaneous platelet glycoprotein IIb/IIIa integrin blockade and front-loaded tissue plasminogen activator in acute myocardial infarction: Results from a randomized trial (1996) (8)
First in Man Pilot Feasibility Study in Extracranial Carotid Robotic-Assisted Endovascular Intervention. (2020) (8)
Description of patients undergoing high risk angioplasty. Analyses of various databases. (1995) (8)
Therapeutic strategies for cardiogenic shock (2004) (8)
Combining clinical and angiographic variables for estimating risk of target lesion revascularization after drug eluting stent placement. (2017) (8)
Factors influencing the outcome of balloon aortic valvuloplasty in the elderly. (1990) (8)
Emerging Transcatheter Options for Tricuspid Regurgitation. (2017) (8)
A Risk-Benefit Assessment of Abciximab in Angioplasty (1999) (8)
Long-term clinical outcomes after percutaneous coronary intervention for unprotected left main coronary artery in heart transplant patients with cardiac allograft vasculopathy. (2012) (7)
Comparison of Outcomes After Transcatheter vs Surgical Aortic Valve Replacement Among Patients at Intermediate Operative Risk With a History of Coronary Artery Bypass Graft Surgery: A Post Hoc Analysis of the SURTAVI Randomized Clinical Trial. (2019) (7)
In‐hospital and one year outcomes with drug‐eluting versus bare metal stents in large native coronary arteries: A report from the evaluation of drug‐eluting stents and ischemic events registry (2013) (7)
In‐Hospital and 1‐year outcomes with drug‐eluting versus bare metal stents in saphenous vein graft intervention: A report from the EVENT registry (2012) (7)
Clinical Implications of Physical Function and Resilience in Patients Undergoing Transcatheter Aortic Valve Replacement (2020) (7)
Statin Therapy and the Acute Inflammatory Response After Coronary Artery Bypass Grafting (2001) (7)
Heparin-associated anti-Xa activity and platelet-derived prothrombotic and proinflammatory biomarkers in moderate to high-risk patients with acute coronary syndrome (2011) (7)
Percutaneous paravalvular repair: guidance using live 3-dimensional transesophageal echocardiography. (2009) (7)
The Value of Left Ventricular Support in Patients With Reduced Left Ventricular Function Undergoing Extensive Revascularization: An Analysis From the PROTECT-II Randomized Trial. (2019) (7)
Delayed Coronary Obstruction After TAVR: A Call for Vigilance. (2018) (7)
Glycoprotein IIb-IIIa antagonists in percutaneous coronary interventions and acute coronary syndromes. (1998) (7)
Combination therapy for acute myocardial infarction: will it survive? (2003) (6)
Use of bare-mounted Palmaz-Schatz stents employing the stent saddle technique on the delivery balloon: a single center experience. (1997) (6)
Case report: It wasn't cupid: multimodality imaging of inferior vena cava filter fracture with strut migration to the interventricular septum. (2014) (6)
Acute coronary syndromes: from the emergency department to the catheterization laboratory-integrating evidence from recent ACS/NSTEMI trials into clinical practice: an evidence-based review of recent clinical trial results and report on a roundtable discussion. (2011) (6)
Antiplatelet therapy for treatment of acute coronary syndromes. (1999) (6)
Clinical Utility of CT Fusion Imaging in Guiding Trans-catheter Paravalvular Leak Closure (2019) (6)
Outcomes of patients with moderate-to-severe Ischemia excluded from the ischemia trial (2021) (6)
Are Immature Platelets Growing Up?: Toward a New Marker of Antiplatelet Drug Resistance. (2016) (6)
Effect of clopidogrel pretreatment on ischemic complications of percutaneous coronary intervention among bivalirudin-treated patients (from the EVENT registry). (2011) (6)
Abciximab + tPA Improves Coronary Flow in a Wide Range of Subgroups: Results from TIMI 14 (1998) (6)
Thrombolytic therapy for patients with prior percutaneous transluminal coronary angioplasty and subsequent acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. (1996) (6)
Clopidogrel and calcium-channel antagonists: another drug-drug interaction for the ever-wary clinician? (2008) (6)
A Paradox between LV Mass Regression and Hemodynamic Improvement after Surgical and Transcatheter Aortic Valve Replacement (2017) (6)
Transcatheter Mitral Valve Repair with MitraClip for Severe Mitral Regurgitation and Cardiogenic Shock During the COVID-19 Pandemic (2020) (5)
Abstract 9150: Re-Elevation of Troponin Following Percutaneous Coronary Intervention Significantly Predicts 1-Year Mortality in Patients with High-risk Non-ST-Segment Elevation Acute Coronary Syndromes (2011) (5)
A 24-Month Interventional Cardiology Fellowship: Learning Motor Skills Through Blocked Repetition. (2017) (5)
Assessing Platelet Function in Clinical Trials (2005) (5)
Percutaneous transluminal coronary angioplasty: is what we see what we get? (1990) (5)
Combined Transcatheter Aortic and Mitral Valve Interventions: Insights From a National Database. (2021) (5)
Bivalirudin, thrombin and platelets: clinical implications and future directions. (2003) (5)
Helicopter transport of patients with acute myocardial infarction. (1988) (5)
Transcatheter Mitral Valve Replacement for Native and Failed Bioprosthetic Mitral Valves. (2017) (5)
Long-Term Outcomes of Drug-Eluting Stents Versus Bare-Metal Stents in End-Stage Renal Disease Patients on Dialysis: A Systematic Review and Meta-Analysis (2018) (5)
Thrombocytopenia in a large, international trial of the GP IIb/IIIa inhibitor eptitibatide in patients with acute coronary syndromes (1998) (5)
Transesophageal echocardiography-guided percutaneous intervention for a mitral valve leaflet perforation. (2015) (5)
TCT-375 Optimizing Rotational Atherectomy in High-Risk Percutaneous Coronary Interventions. Insights from the PROTECT II study (2012) (5)
Glycoprotein IIb-IIIa inhibition with abciximab and postprocedural risk assessment: lessons from the evaluation of platelet IIb/IIIa inhibitor for stenting trial and implication for ad hoc use of glycoprotein IIb-IIIa antagonists. (2002) (5)
Low molecular weight heparins (2000) (5)
In-hospital outcomes with transfemoral versus transapical access for transcatheter aortic valve replacement in patients with peripheral arterial disease. (2019) (5)
Thrombolytic therapy in acute myocardial infarction (1988) (5)
Late Arrhythmias in Patients with New-Onset Persistent Left Bundle Branch Block After Transcatheter Aortic Valve Replacement Using a Balloon-Expandable Valve. (2021) (5)
Mechanical Prosthetic Aortic Valve Thrombosis Complicated by an Acute Coronary Syndrome During Fibrinolysis (2020) (5)
861-1 Direct, selective, factor Xa inhibition in patients with non-ST elevation acute coronary syndromes from the United States, Canada, and Japan: Results of the XaNADU-ACS trial (2004) (5)
Images in cardiovascular medicine. Fistula between left main, left anterior descending, and pulmonary arteries. (1998) (5)
Surgical considerations on the use of the percutaneous ventricular assist device TandemHeart in critical aortic valve stenosis. (2009) (4)
Initial impact of drug-eluting stent use on the spectrum of patients undergoing percutaneous coronary intervention (2006) (4)
Safety issues surrounding use of platelet GP IIb/IIIa antagonists: Reversibility and readministration (1999) (4)
Short-Term Outcomes with Direct Aortic Access for Transcatheter Aortic Valve Replacement. (2015) (4)
Prostaglandin E1 does not accelerate rTPA-induced thrombolysis in acute myocardial infarction. (1994) (4)
Ticlopidine Enhances the Platelet Inhibitory Capacity of Abciximab In Vitro (2004) (4)
Goals of thrombolytic therapy. (1991) (4)
Transcatheter Edge-to-Edge Repair With MitraClip in Systolic Heart Failure With Ischemic Versus Nonischemic Cardiomyopathy. (2020) (4)
Expanding the Roster: Developing New Inhibitors of Intravascular Thrombosis. (2015) (4)
IMPELLA IMPROVES CLINICAL OUTCOMES WHEN EXTENSIVE REVASCULARIZATION IS PERFORMED: THE PROTECT II STUDY (2012) (4)
Transcatheter Aortic Valve Replacement for Perceval Sutureless Aortic Valve Failure. (2017) (4)
When to SAVR in the age of TAVR? A perspective on surgical aortic valve replacement in 2018. (2018) (4)
Suicide left ventricle due to conduction disturbance following transcatheter aortic valve replacement and reversal with restoration of sinus rhythm: is there life after death? (2015) (4)
Three-year outcomes with a contemporary self-expanding transcatheter valve from the Evolut PRO US Clinical Study. (2020) (4)
Structural Valve Deterioration After Self-Expanding Transcatheter or Surgical Aortic Valve Implantation in Patients at Intermediate or High Risk. (2022) (4)
Clinical trials of conjunctive anticoagulant strategies in thrombolysis. (1996) (4)
The Impact of Postrandomization Crossover of Therapy in Acute Coronary Syndromes Care (2011) (4)
Anticoagulant therapy in acute myocardial infarction: demonstration of a selection bias in a retrospective study. (1980) (4)
Physicians' Use of Heparin Following Thrombolytic Therapy: An International Perspective (1997) (4)
Predicting and measuring mortality risk after transcatheter aortic valve replacement (2021) (4)
Effectiveness of videotaped dietary instruction for patients hospitalized with cardiovascular disease. (1992) (4)
Characterization of myocardial infarction as an end point in two large trials of acute coronary syndromes. (2005) (4)
Von Willebrand factor and the aortic valve: Concepts that are important in the transcatheter aortic valve replacement era. (2018) (4)
Should Interventional Cardiologists Super-Subspecialize?: Moving From Patient Selection to Operator Selection. (2021) (4)
Six-month outcomes of percutaneous coronary balloon angioplasty in acute coronary syndromes: Results from the PURSUIT trial. (2004) (4)
Von Willebrand factor, paravalvular leak, and a new vista for TAVR. (2016) (3)
Recombinant Hirudin for Unstable Angina Pectoris (2005) (3)
Relationship of persistently elevated soluble interleukin-2 levels after heart transplant to allograft arteriopathy (1991) (3)
Initial experience with a novel direct factor Xa inhibitor in percutaneous coronary intervention (2002) (3)
Meta-Analysis Investigating the Role of Optical Coherence Tomography Versus Intravascular Ultrasound in Low-Risk Percutaneous Coronary Intervention. (2021) (3)
Percutaneous transluminal coronary angioplasty: Its role in cardiogenic shock (1992) (3)
Combination of a direct thrombin inhibitor, argatroban, and glycoprotein IIb/IIIa inhibitor is effective and safe in patients undergoing percutaneous coronary intervention (2003) (3)
Three-Year Outcomes After Transcatheter or Surgical Aortic Valve Replacement in Low-Risk Patients with Aortic Stenosis. (2023) (3)
Transcatheter Treatment of Apicoaortic Conduit Dysfunction (2015) (3)
Vascular changes and black hole phenomenon after coronary brachytherapy: a pathologically distinct entity. (2008) (3)
Impact of computerized dosing on eptifibatide-associated bleeding and mortality. (2009) (3)
Abstract 4409: Phenotypic Plasticity of LMNA Mutations in Cardiovascular System Includes Isolated Cardiac Progeria, Dilated and Hypertrophic Cardiomyopathies, Atrial Fibrillation, Conduction Defects and Degenerative Valvular Diseases (2008) (3)
Three-dimensional transesophageal echocardiogram provides real-time guidance during percutaneous paravalvular mitral repair. (2008) (3)
Propensity-Matched Comparison of Evolut-R Transcatheter Aortic Valve Implantation With Surgery in Intermediate-Risk Patients (from the SURTAVI Trial). (2020) (3)
Primary and secondary safety endpoints from IMPACT II. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. (1997) (3)
Watching a Procedure Evolve: Sequential Findings From the TVT Registry. (2015) (3)
Watching a Procedure Evolve: Sequential Findings From the TVT Registry. (2016) (2)
National trends and outcomes of surgical aortic valve replacement with concomitant mitral valve surgery (2021) (2)
Clinical efficacy of integrilin in unstable angina is accompanied by a modest increase in hemorrhagic risk: the PURSUIT trial (1998) (2)
Abciximab inhibits formation of platelet-derived microparticles despite platelet activation (1998) (2)
Transcatheter Aortic Valve Replacement With Self‐Expandable Supra‐Annular Valves for Degenerated Surgical Bioprostheses: Insights From Transcatheter Valve Therapy Registry (2021) (2)
TCT-70 Incidence, Trends, and Risk Factors for Early Stroke after Transcatheter Aortic Valve Replacement in the First 5 years of US Clinical Practice: Report of the STS/ACC TVT Registry. (2018) (2)
Introduction to transcatheter aortic valve implantation. (2012) (2)
Issues in cardiac intervention for UA/NSTEMI (2001) (2)
TCT-344 Clinical Outcomes of Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients Stratified by STS Score: Results from the SURTAVI Trial (2017) (2)
Optimal dosing of a glycoprotein IIb/IIIa antagonist with simplified renal-based algorithm: pharmacodynamic and clinical findings from PARAGON B (2001) (2)
Bioprosthetic Mitral Transcatheter Transapical Valve‐in‐Valve Implantation for Mitral Stenosis in an End‐Stage Renal Disease Patient (2015) (2)
Late Transcatheter Aortic Valve Thrombosis Leading to Cardiogenic Shock (2022) (2)
The Last Detail: Platelets, Glycoprotein IIb/IIIa Antagonists, and Excipients. (2016) (2)
Transesophageal echocardiographic demonstration of right coronary artery-to-coronary sinus fistula in a heart transplant recipient. (1993) (2)
LONG-TERM PROTECTION FROM MYOCARDIAL ISCHEMIC EVENTS IN A RANDOMIZED TRIALOF BRIEF INTEGRIN BETA 3 BLOCKADE WITH PERCUTANEOUS CORONARY INTERVENTION. COMMENTARY (1997) (2)
Rotational coronary ablation achieves lumen size comparable to balloon angioplasty without stretching the arterial wall (1991) (2)
600.04 Coronary Intervention After Self-Expanding Transcatheter or Surgical Aortic Valve Replacement in the SURTAVI Trial (2019) (2)
Minimally Invasive Repair of Left Ventricular Pseudoaneurysm after Transapical Transcatheter Aortic Valve Replacement. (2016) (2)
Right-to-left intracardiac shunt and constrictive pericarditis following coronary artery bypass surgery. (1987) (2)
Transcatheter Edge to Edge Repair with MitraClip Among Renal Transplant Recipients. (2021) (2)
Patient-Specific Antiplatelet Therapy (2004) (2)
Optimal positioning of self‐expanding valves before deployment decreases paravalvular regurgitation following transcatheter aortic valve replacement (2018) (2)
How Many Roads Lead to Rome? (2016) (2)
Explant vs Redo-TAVR After Transcatheter Valve Failure: Mid-Term Outcomes From the EXPLANTORREDO-TAVR International Registry. (2023) (2)
Five-Year Clinical and Quality of Life Outcomes From the CoreValve US Pivotal Extreme Risk Trial (2021) (2)
Platelet activation in acute myocardial infarction and the rationale for combination therapy (2000) (2)
Heterotopic heart transplantation: catheterization, endomyocardial biopsy, and coronary angiography of the donor heart. (1994) (2)
Biomarkers for Antiplatelet Therapy (2019) (1)
Cardiac Arrest in Young Adults with Ischemic Heart Disease in the United States, 2004-2018. (2022) (1)
OUTCOMES IN THE COREVALVE US HIGH-RISK PIVOTAL TRIAL IN PATIENTS WITH A SOCIETY OF THORACIC SURGEONS PREDICTED RISK OF MORTALITY LESS THAN OR EQUAL TO 7 (2016) (1)
PLATO Study of Ticagrelor Versus Clopidogrel in Patients With High-Risk Acute Coronary Syndromes (2010) (1)
Structural Heart Interventional Training: The Next Steps. (2016) (1)
Platelet Glycoprotein IIb/IIIa Antagonists: Their Interaction with Low-Molecular-Weight Heparins and Direct Thrombin Inhibitors (2003) (1)
TCT-13 5-year Outcomes from the Randomized CoreValve US Pivotal High Risk Trial: Final Results (2018) (1)
30-Day Clinical Outcomes of a Self-Expanding Transcatheter Aortic Valve: The International PORTICO NG Study. (2023) (1)
In Touch But Out of Time: Aggressive Hospital Discharge and Readmissions After Transcatheter Aortic Valve Replacement (2017) (1)
TCT-100 Transcatheter Aortic Valve Replacement in Patients With End-Stage Renal Disease: One Year Outcomes from the CoreValve US Expanded Use Study (2015) (1)
Mitral Valve-in-Valve Versus Repeat Surgical Mitral Valve Replacement in Patients With Failed Mitral Bioprostheses: A Systematic Review and Meta-Analysis (2022) (1)
Role of Platelets in Homing of Endothelial Progenitor Cells to the Site of Vascular Injury. (2005) (1)
CHAPTER 22 – Diagnosis and Treatment of Complications of Coronary and Valvular Interventions (2010) (1)
Synergy of abciximab and ticiopidine in patients undergoing intracoronary stenting (1998) (1)
Idiopathic sinus of Valsalva to right atrial fistula: an unusual origin of right-sided heart failure. (2004) (1)
COMPARISON OF PERCUTANEOUS CORONARY INTERVENTION VERSUS CORONARY ARTERY BYPASS GRAFTING IN OLDER ADULTS WITH UNPROTECTED LEFT MAIN CORONARY ARTERY DISEASE: A META-ANALYSIS AND METAREGRESSION (2019) (1)
Unstable Angina and Non-ST Segment Elevation Myocardial Infarction (Acute Coronary Syndromes) (2013) (1)
Simultaneous Transfemoral Mitral and Tricuspid Valve in Ring Implantation: First Case Report with Edwards Sapien 3 Valve. (2019) (1)
VWF, ADAMTS13, and acute coronary syndromes. (2016) (1)
Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Combined Chronic Kidney and Liver Disease. (2021) (1)
Remodeling of Self-Expanding Transcatheter Aortic Valve Is Responsible for Regression of Paravalvular Aortic Regurgitation: An Observation From Corevalve Pivotal Trial (2015) (1)
Abstract 4557: Mode of Death After Contemporary Percutaneous Coronary Intervention: A Report From the EVENT Multicenter Registry (2009) (1)
Adenosine echocardiography with or without handgrip in the diagnosis of coronary artery disease: Comparison with exercise echocardiography (1991) (1)
Optimizing Management of Patients With Atrial Fibrillation Following Transcatheter Aortic Valve Replacement: The Importance of Distinguishing Pre-Existing From New Onset Atrial Fibrillation. (2017) (1)
Risk factors and outcomes in patients with ventricular septal defects (VSD) complicating acute MI (1996) (1)
At Arm's Length: Radiation Safety During Radial Percutaneous Coronary Intervention. (2017) (1)
Abciximab (Reopro) Achieves Effective Platelet Inhibition in St-Elevation MI: A TIMI 14 Substudy (1998) (1)
Rotational Atherectomy Increases Circulating Platelet-Monocyte Complexes (1998) (1)
Beyond pharmacology in heart attacks : coronary stents and stem cells (2007) (1)
Novel Antiplatelet and Antithrombotic Agents in the Treatment of Non-ST-Segment Elevation Coronary Ischemia (1999) (1)
Nonlinear binding models suggest that ABCIXIMAB (AB) Pharmacokinetics (PK) and pharmacodynamics (PD) are target‐mediated (2004) (1)
TCT-593 Predicting Acute Kidney Injury in Patients Undergoing Transcatheter Aortic Valve Replacement: Testing the Mehran Contrast Induced Nephropathy Score (2018) (1)
Transcatheter and Doppler waveform correlation in transcatheter aortic valve replacement (2018) (1)
TCT CONNECT-4 Surgical EXPLANTation After Transcatheter Aortic Valve Replacement Failure: Midterm Outcomes From the EXPLANT-TAVR International Registry (2020) (1)
Glycoprotein IIb/IIIa antagonists in the setting of rescue percutaneous coronary intervention. (2002) (1)
Late-breaking Basic Science Abstracts from the American Heart Association's Scientific Sessions 2012 2012 Late-breaking Basic Science Abstracts Late-breaking Basic Science Oral Session 22925 Cardiac Myosin Binding Protein C Is an Ultra-early and Cardiac-specific Biomarker of Myocardial Necrosis Repl (2012) (1)
Aspirin With or Without Statin in Individuals Without Atherosclerotic Cardiovascular Disease Across Risk Categories (2023) (1)
Coronary Heart Disease / Myocardial Infarction Diminished Vascular Response to Inhibition of Endothelium-Derived Nitric Oxide and Enhanced Vasoconstriction to Exogenously Administered Endothelin-1 in Clinically Healthy Smokers (2005) (1)
Is This a Good Time to Revisit the Tropics?: Platelet Function Testing in Patients With Acute Coronary Syndromes. (2021) (1)
Monitoring Platelet Aggregation (1999) (1)
Clinical impact of tricuspid regurgitation on transcatheter edge-to-edge mitral valve repair for mitral regurgitation. (2022) (1)
TCT-87 Clinical Outcomes of Optical Coherence Tomography-Guided Compared With Intravascular Ultrasound-Guided Percutaneous Coronary Intervention: A Meta-Analysis (2021) (1)
When Prevention is Truly Better than Cure: Contrast-Associated Acute Kidney Injury in Percutaneous Coronary Intervention (2022) (1)
Abstract P271: Mortality Benefit With Drug-Eluting Stents in Observational Studies: Fact or Artifact? Insights From the Prospective, Multicenter EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) Registry (2011) (1)
PREDICTION OF OPTIMAL DEPLOYMENT ANGLE FOR TAVR: FEASIBILITY OF CT ANGIOGRAPHY AND NON–CONTRAST DYNACT IMAGE REGISTRATION BASED APPROACH AND ITS POTENTIAL IMPLICATION ON LIMITING CONTRAST VOLUME (2013) (1)
Diagnosis and Management of Late-presentation ST-elevation Myocardial Infarction and Complications. (2021) (1)
600.25 A Novel 3-Dimensional Imaging Platform for Device Sizing in Transcatheter Aortic Valve Implantation (2019) (1)
IMPROVEMENT IN LEFT VENTRICULAR EJECTION FRACTION AFTER PERCUTANEOUS CORONARY INTERVENTIONS IN PATIENTS WITH CHRONIC TOTAL OCCLUSION: A SINGLE CENTER STUDY EVALUATING CARDIOVASCULAR OUTCOMES (2023) (0)
Abstract 9844: Clinical Outcomes of Saphenous Vein Graft Interventions Using Drug Eluting Stents Compared with Bare Metal Stents: A Comprehensive Meta-Analysis of All Randomized Clinical Trials (2011) (0)
Interventional Cardiology spirin and Clopidogrel Drug Response in atients Undergoing Percutaneous Coronary Intervention he Role of Dual Drug Resistance (2016) (0)
THE IMPACT OF PREOPERATIVE RENAL DYSFUNCTION ON THE OUTCOMES OF PATIENTS UNDERGOING SURGICAL VERSUS TRANSCATHETER AORTIC VALVE REPLACEMENT: AN ANALYSIS FROM THE COREVALVE US PIVOTAL HIGH RISK TRIAL (2017) (0)
INCIDENCE AND OUTCOMES OF PATIENTS REQUIRING SURGICAL BAIL-OUT DURING TRANSCATHETER AORTIC VALVE REPLACEMENT: A REPORT FROM THE NCDR® STS/ACC TRANSCATHETER VALVE THERAPY (TVT) REGISTRY (2017) (0)
Serial quantitative angiography may not improve the detection of coronary arteriopathy after heart transplant (1991) (0)
Bivalirudin reduces ischemic and hemorrhagic complications of percutaneous coronary intervention: Pooled data from 10 prospective studies in 6,134 patients (2003) (0)
Usefulness of magnetic resonance imaging for assessing rejection after heterotopic heart transplantation (1991) (0)
PERCUT A NEOUS REP A IR OF MITRAL PA RA VA LV UL A R R EGURGIT AT ION (2008) (0)
Commentary: Pacemaker requirement with rapid-deployment aortic valves. (2020) (0)
Is it time to join the cult? Radial access and percutaneous coronary intervention. (2015) (0)
Very Late Migration of Balloon-Expandable Transcatheter Aortic Valve. (2018) (0)
Clopidogrel pretreatment does not influence the relative efficacy of bivalirudin with provisional GPIIb/IIIa blockade vs heparin with routine GPIIb/IIIa blockade. A REPLACE-2 substudy (2003) (0)
IMPACT OF FEMALE GENDER ON MORTALITY AFTER ISOLATED CORONARY ARTERY BYPASS GRAFTING (2013) (0)
STAGING OF CARDIAC DAMAGE IN AORTIC REGURGITATION (2021) (0)
Searching for the ceiling: new reflections on the disposition and metabolism of clopidogrel. (2008) (0)
TCT-20 Five-Year Follow-Up From the CoreValve Expanded Use Transcatheter Aortic Valve-in-Surgical Aortic Valve Study (2021) (0)
Tough Crossing: A Challenging Case of Valve-in-Valve Transcatheter Tricuspid Valve Replacement (2022) (0)
Antiplatelet Therapy in Patients with Coronary Artery Disease (2017) (0)
TCT CONNECT-109 1-Year Outcomes With Lotus Edge: The REPRISE III Nested Registry (2020) (0)
At 5 years, transcatheter aortic valve replacement had similar rates of mortality and stroke as surgical aortic valve replacement in high-risk patients (2015) (0)
MITRAL VALVE PARAVALVULAR LEAK CLOSURE USING A ROBOTIC CATHETER SYSTEM (2016) (0)
Valve-in-Valve Transcatheter Aortic Valve Replacement With a Repositionable, Self-Expanding Valve (2019) (0)
TCT-416 Clinical Impact of Tricuspid Regurgitation on Transcatheter Edge-to-Edge Mitral Valve Repair for Secondary Mitral Regurgitation: A Systematic Review and Meta-Analysis (2021) (0)
Prevention of reinfarction using half-dose reteplase and abciximab: observation from the GUSTO-5 trial (2002) (0)
PCI OR CORONARY ARTERY BYPASS GRAFT: IMPLICATIONS IN END–STAGE RENAL DISEASE PATIENTS (2013) (0)
in Patients Undergoing Percutaneous Coronary Intervention (2013) (0)
Abstract 14469: Optimal Use of Drug-Eluting Stents in PCI: Implications of Healthcare Policy in Real-World Practice (2011) (0)
What Happens in the Cath Lab Stays in the Cath Lab, or Does It?: Intraprocedural Thrombotic Events in Patients With Acute Coronary Syndromes. (2016) (0)
Whit ombining Antiplatelet nd Anticoagulant Therapies (0)
Antiplatelet therapy and coronary interventions: childhood friends or permanent partners? (2002) (0)
Editorial: Minding the Gradient — Valve-in-Valve Transcatheter Aortic Valve Replacement vs. Redo Surgical Aortic Valve Replacements for Surgical Bioprosthetic Valve Failure (2022) (0)
Platelet Glycoprotein IIb/IIIa Inhibitors Reduce Mortality in Diabetic Patients With Non–ST-Segment-Elevation Acute Coronary Syndromes Clinical Investigation and Reports (2001) (0)
TCT-394 Late Outcomes After Transcatheter Aortic Valve Replacement With a Mechanically Expanded Versus Self-Expandable Valve: Final 5-Year Results From the REPRISE III Randomized Trial (2021) (0)
Is aspirin resistance valid? (2006) (0)
DOES A LOSS OF FUNCTION POLYMORPHISM OF CYP2C19 MODULATE THE INTERACTION BETWEEN CLOPIDOGREL AND PROTON PUMP INHIBITORS? RESULTS OF A PARELLEL CROSSOVER TRIAL (2011) (0)
Role of Activated Platelets in the Homing, Maturation, and Differentiation of Endotheleal Progenitor Cells (EPCs) to Vascular Subendotheleal Matrix. (2006) (0)
Too Thick to Cut With SISRs. (2018) (0)
P1854Clinical implications of physical function and resilience in patients undergoing transcatheter aortic valve implantation (2019) (0)
Guest Editor Neal Kleiman Leads Issue on the Current Status of Stents. (2018) (0)
TreatmentIntravenous nitroglycerin is highly effective in preventing recurrent or refractory ischemia in patients with unstable angina secondary to restenosis following PTCA (2000) (0)
Abstract 8888: Statin Therapy In Patients with Chronic Kidney Disease Undergoing Percutaneous Coronary Interventions Is Associated with Better One Year Outcomes. An Analysis from the Evaluation of Drug Eluting Stents and Ischemic Events (EVENT) Registry (2011) (0)
IMPACT OF PERIPROCEDURAL MYOCARDIAL BIOMARKER ELEVATION ON MORTALITY FOLLOWING PERCUTANEOUS CORONARY INTERVENTION: A POOLED PATIENT-LEVEL (N=13452) ANALYSIS OF CONTEMPORARY STENT TRIALS (2018) (0)
Journal Pre-proof Triage Considerations for Patients Referred for Structural Heart Disease Intervention During the Coronavirus Disease 2019 (COVID-19) Pandemic: An ACC /SCAI Consensus Statement Intervention the (2020) (0)
TCT-303 Balloon Predilation in Transcatheter Aortic Valve Replacement with Self-Expanding Valves (2017) (0)
List of Contributors (2019) (0)
TCT-432 Predictors Of Upper Extremity Arterial Tortuosity Encountered During Transradial Access: Results From A Large National Registry (2015) (0)
MACHINE LEARNING DERIVED RISK-PREDICTION MODEL FOR IN-HOSPITAL SURVIVAL IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION BEFORE ORGAN TRANSPLANT (2023) (0)
RESIST A NCE TO ORAL ANTIPL AT ELET AGENTS: FA CT O R FA NT A SY? (2008) (0)
PLATELETS AND VON WILLEBRAND FACTOR INTERACTIONS AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR): ASSOCIATION WITH THROMBOCYTOPENIA AND THROMBOSIS (2017) (0)
List of Contributors (2019) (0)
New therapeutic approaches Beyond pharmacology in heart attacks : coronary stents and stem cells (2007) (0)
Appendix Participating Institutions , Principal Investigators , and Study Coordinators (2001) (0)
Highway to the heart or one more for the road? The continued life of direct aortic access for transcatheter aortic valve replacement. (2016) (0)
Effects of low altitude on heart rate variability and ventricular late potentials in patients with congestive heart failure. (1998) (0)
Direct Oral Anticoagulants Versus Vitamin K Antagonists in the Treatment of Left Ventricular Thrombi (2021) (0)
WITH THE ROTABLATOR (2017) (0)
Comparative Outcomes of Transcatheter Aortic Valve Implantation and Mitral Transcatheter Edge-to-Edge Repair: Same Versus Different Hospitalization. (2021) (0)
Ventricular Embolization of Mitral Valve in Valve Rescued With a Second Valve. (2023) (0)
Neural networks pattern recognition to predict abciximab pharmacodynamics using readily available patient characteristics (2003) (0)
Abstract 2216: Polyvascular Disease - A Novel Risk Factor for Worse Ischemic and Bleeding Outcomes in Acute Coronary Syndromes (2007) (0)
Low molecular weight heparins (2000) (0)
VOLUMES AND OUTCOMES OF TRICUSPID VALVE SURGERY WITH CONCOMITANT MITRAL VALVE SURGERY (2021) (0)
IMPROVED OUTCOMES WITH DRUG ELUTING VERSUS BARE METAL STENTS IN SAPHENOUS VEIN GRAFT INTERVENTION: A REPORT FROM THE EVALUATION OF DRUG-ELUTING STENTS AND ISCHEMIC EVENTS (EVENT) REGISTRY (2011) (0)
Erratum to: Immature platelet fraction (IPF) determined with an automated method predicts clopidogrel hyporesponsiveness (2012) (0)
Antiplatelet therapy and coronary interventions: childhood friends or permanent partners? (2002) (0)
Stenting of a left main coronary artery compressed by dilated pulmonary artery (2013) (0)
Acute coronary syndrome – thinking beyond the plaque 1129 (0)
Arteriographic demonstration of coronary artery spasm during thrombolysis. (1988) (0)
The Management of Heart Failure in the Age of Reperfusion (1994) (0)
[Prognostic significance of initial blood glucose levels in acute myocardial infarction]. (1982) (0)
Morphologic Analysis of Coronary Stenoses by Coronary Angiography: Subjective Variability and Accuracy (1997) (0)
Coronary Artery Damage Induces Endothelial Progenitor Cell Recruitment and High Levels of Circulating EPCs Correlate with Coronary Artery Collaterals Formation. (2005) (0)
Reader's Comments Association of Peri-Procedural Major Bleeding With Outcomes in Patients Undergoing Transcatheter Mitral Edge-To-Edge Repair. (2021) (0)
Balancing hemostasis and thrombosis in interventional vascular medicine and surgery. (2011) (0)
Atherosclerosis / Coronary Heart Disease Short-term Cholesterol Lowering Decreases Size and Severity of Perfusion Abnormalities by Positron Emission Tomography After Dipyridamole in Patients With Coronary Artery Disease : A Potential Noninvasive Marker of Healing Coronary Endothelium (2005) (0)
LEAVE NO STONE UNTURNED - COMPLETE REVASCULARIZATION OF SVG TO OM IN-STENT RESTENOSIS AND LM TO LAD CTO (IN-STENT RESTENOSIS) IN A TAKAYASU’S PATEINT WITH A HISTORY OF COROANRY INVOLVEMENT AND REDO CABG. (2022) (0)
TCT CONNECT-455 Reinterventions After Transcatheter Aortic Valve Replacement With a Supra-Annular Self-Expanding Bioprosthesis (2020) (0)
Abstract 13250: Percutaneous Coronary Intervention with Drug-Eluting Stents Versus Coronary Artery Bypass Graft Surgery for Unprotected Left Main Coronary Artery Stenosis: A Meta-Analysis of Randomized Clinical Trials (2011) (0)
COMBINATION OF INVASIVE ANGIOGRAPHY AND CORONARY COMPUTED TOMOGRAPHY ANGIOGRAPHY AS A NOVEL IMAGING FUSION MODALITY TO IMPROVE ANTEGRADE REVASCULARIZATION OF CORONARY CHRONIC TOTAL OCCLUSION (2019) (0)
Aspirin , Non-Steroidal Anti-Inflammatories , and CAD spirin Dose and Six-Month utcome After an Acute Coronary Syndrome (2004) (0)
Assessing Short-Term Risk in Acute Coronary Syndrome: The Role of P2Y12 Inhibition (2020) (0)
Abstract 13919: Comparison of Clinical Outcomes After Trans-catheter Aortic Valve Implantation in Men and Women for Severe Aortic Stenosis (2013) (0)
Stenting: the Latest Frontier in Percutaneous Intervention. (2018) (0)
PERI-VALVE THROMBUS AFTER VALVE IN VALVE TRANSCATHETER AORTIC VALVE REPLACEMENT FOR BIOPROSTHETIC AORTIC VALVE STENOSIS (2019) (0)
Mechanisms of death in low risk patients after transcatheter or surgical aortic valve replacement. (2022) (0)
1043-65 Simple risk score predicts myocardial infarction and cardiovascular death at 30 days after percutaneous coronary intervention: An analysis of the REPLACE-2 and TARGET data (2004) (0)
A Multicenter, Randomized Angiographic Trial (2005) (0)
Thrombolytic treatment for acute myocardial infarction. (1988) (0)
At Arms Length: Radiation Safety During Radial PCI (2017) (0)
Assessment of Repeat Revascularization in Percutaneous Coronary Intervention Randomized Controlled Trials as a Surrogate for Mortality:A Meta-Regression Analysis. (2022) (0)
1043-66 Procedural predictors of creatine kinase-MB elevations in the REPLACE-2 study (2004) (0)
Could clopidogrel's platelet inhibition be enhanced by an increased loading dose and eptifibatide? (2005) (0)
Impact of Clopidogrel Pretreatment on Ischemic Complications of PCI among Bivalirudin-Treated Patients: Results from the EVENT Registry (2010) (0)
TCT-68 The use of Percutaneous Left Ventricular Assist Device vs Intra-aortic Balloon Pump for Hemodynamic Support During High Risk PCI (2012) (0)
TCT-484: Cost-effectiveness and Clinical Outcomes of Impella Hemodynamic Support Compared with Intra- Aortic Balloon Pump in High Risk Patients Receiving PCI: Results from the PROTECT II Trial (2016) (0)
Dethroning Contrast Angiography (2022) (0)
BIVALIRUDIN VS. UNFRACTIONATED HEPARIN IN PATIENTS UNDERGOING STENTING OF SAPHENOUS VEIN GRAFTS. AN ANALYSIS FROM THE EVENT REGISTRY (2010) (0)
IMPACT OF RENIN-ANGIOTENSIN SYSTEM INHIBITORS ON CLINICAL OUTCOMES IN PATIENTS WITH SEVERE SYMPTOMATIC AORTIC STENOSIS UNDERGOING TRANSCATHETER AORTIC VALVE REPLACEMENT WITH A SELF-EXPANDING BIOPROSTHESIS (2022) (0)
TCT-683 Early Stroke After Implantation of a Self-Expanding Transcatheter Aortic Valve Prosthesis: Experience From the CoreValve Clinical Trials (2015) (0)
Site-level variability in the processes of care and outcomes over time among patients with COVID-19 and myocardial injury: Insights from the American Heart Association's COVID-19 Cardiovascular Disease Registry (2023) (0)
High-speed coronary rotational angioplasty with the rotablator (1992) (0)
Experience With a Magnetic avigation System for Percutaneous Coronary ntervention in Complex Coronary Artery Lesions (2016) (0)
INITIAL USE OF THE EVOLUT PRO SELF-EXPANDING TRANSCATHETER AORTIC VALVE (2017) (0)
WHEN ECHOCARDIOGRAPHY IS CHALLENGING IN LOCALIZING BIOPROSTHETIC AORTIC REGURGITATION - DYE DON’T LIE …!! (2023) (0)
PREDICTORS OF MORTALITY IN PATIENTS UNDERGOING MITRACLIP FOR SEVERE MITRAL REGURGITATION (2019) (0)
FACTORS ASSOCIATED WITH USE OF NEWER ANTIPLATELET AGENTS IN PATIENTS UNDERGOING DRUG ELUTING STENT PLACEMENT: ANALYSIS FROM THE PINNACLE® REGISTRY (2015) (0)
OPTIMAL POSITIONING OF MEDTRONIC CORE VALVE BEFORE DEPLOYMENT DECREASES PARAVALVULAR REGURGITATION POST TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR) (2018) (0)
TREATMENT OF REFRACTORY CORONARY ARTERY SPASM WITH PERCUTANEOUS CORONARY INTERVENTION (2017) (0)
CRT-700.09 Impact of Mitral Annular Calcification on Outcomes After Mitral Transcatheter Edge-to-Edge Repair (2023) (0)
11. Aortic Stenosis (2016) (0)
Direct Aortic Access Transcatheter Aortic Valve Replacement (2015) (0)
Optimizing Therapy in Acute Coronary Syndromes and Percutaneous Coronary Intervention (2005) (0)
WHAT IS THE OPTIMAL RATE OF DRUG-ELUTING STENT USE? INSIGHTS FROM TEMPORAL ANALYSIS OF THE MULTICENTER EVENT REGISTRY (2010) (0)
Does Orientation Matter? (2018) (0)
CHRONIC TOTAL OCCLUSIONS: IMPACT OF SUCCESSFUL AND FAILED RECANALIZATION ON SHORT AND LONG–TERM SURVIVAL (2013) (0)
Combination therapy for acute myocardial infarction**Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology. (2003) (0)
Will machine learning help us predict strokes during percutaneous valve procedures? (2022) (0)
Abstract 5993: One-Year Clinical Outcomes of Sirolimus-Eluting vs. Paclitaxel-Eluting Stents in Unselected Patients: Results from the Multicenter EVENT Registry (2008) (0)
Should prasugrel or clopidogrel be used in patients with ACS? (2008) (0)
The Complexities of Redo TAVR. (2022) (0)
600.26 Usefulness of Skeletal Muscle Area Detected by Computed Tomography to Predict Mortality in Patients Undergoing Transcatheter Aortic Valve Replacement: A Meta-Analysis (2019) (0)
OUTCOMES AND SOCIETY OF THORACIC SURGEONS RISK SCORE: A SUBANALYSIS OF THE REPRISE III RANDOMIZED CLINICAL TRIAL (2018) (0)
Abciximab reduces death and myocardial infarction but not target vessel revascularization in diabetics undergoing percutaneous transluminal coronary angioplasty The EPILOG experience (1997) (0)
COOPERATIVE STUDIES Confronting the Issues of Patient Safety and Investigator Conflict of Interest in an International Clinical Trial of Myocardial Reperfusion (2016) (0)
IMMATURE PLATELET COUNT (IPC) AS A PREDICTOR OF ADVERSE CLINICAL OUTCOMES (2014) (0)
Intraprocedural Doppler and Invasive Hemodynamic Profiling Predict Clinical Outcomes After Mitral TEER (2023) (0)
Surgical bailout for left ventricular outflow tract obstruction following a complicated mitral valve-in-valve procedure. (2020) (0)
EARLY RECOVERY OF LEFT VENTRICULAR EJECTION FRACTION AFTER COREVALVE TAVR: FINDINGS FROM THE COREVALVE PIVOTAL TRIALS (2016) (0)
Abstract 11770: Clinical Outcomes of Optical Coherence Tomography-Guided Compared With Intravascular Ultrasound-Guided in Low-Risk Percutaneous Coronary Intervention: A Meta-Analysis (2021) (0)
Interventional approaches to acute coronary syndromes (2012) (0)
Propensity-Matched Outcomes Comparing TAVR in Bicuspid vs Surgery in Tricuspid Aortic Valve Stenosis (2022) (0)
Upping the Transcatheter Edge-to-Edge Repair Game: Patient Selection Based on Newly Described Echocardiographic Measurements. (2022) (0)
ED to catheterization laboratory: a roundtable integrating trials with practice. (2011) (0)
Percutaneous Repair Of Mitral Paravalvular Regurgitation (2008) (0)
LONG-TERM OUTCOMES OF TRANSCATHETER AORTIC VALVE REPLACEMENT IN PATIENTS WITH END-STAGE RENAL DISEASE ON DIALYSIS (2022) (0)
Long-term Outcomes of Transcatheter Aortic Valve Replacement With the Lotus Valve vs CoreValve/EvolutR (2022) (0)
DRUG-ELUTING VERSUS BARE-METAL STENTING IN LARGE CORONARY ARTERIES IN THE EVENT REGISTRY (2011) (0)
Balloon Predilation in Transcatheter Aortic Valve Replacement with Self-expanding Valves (2019) (0)
Featured Clinical Research, Part II (2019) (0)
TCT-433 Expansion of Ileofemoral Access to <5 mm with Recollapsible Sheath in High Risk TAVR Patients is Feasible with Zero Complication (2015) (0)
Trends in outcomes of hospitalized adults undergoing percutaneous balloon mitral valvuloplasty in the United States. (2021) (0)
Future Imaging and Guidance for Endovascular Procedures (2010) (0)
Percutaneous myocardial laser revascularisation may not be effective in severe angina. (2006) (0)
Never So Simple: Bedside Measurement of Platelet Reactivity and the Risk of Stroke After Coronary Stenting. (2018) (0)
CENTRAL AND PARAVALVULAR REGURGITATION IN A PATIENT WITH A HISTORY OF A BIOPROSTHETIC AORTIC VALVE (2020) (0)
INTRAPROCEDURAL HEMODYNAMIC RISK PROFILING USING PULMONARY VEIN FLOW CHANGE TO PREDICT CLINICAL OUTCOMES AFTER MITRAL TRANSCATHETER EDGE TO EDGE REPAIR (TEER) (2023) (0)
Resistance To Oral Antiplatelet Agents: Fact Or Fantasy? (2008) (0)
Prognostic Signi fi cance of Bleeding Location and Severity Among Patients With Acute Coronary Syndromes (0)
MACHINE LEARNING DERIVED RISK-PREDICTION MODEL FOR 30-DAY READMISSION FOLLOWING MITRAL TRANSCATHETER EDGE TO EDGE REPAIR (2023) (0)
QCA to guide treatment of inter-clip mitral regurgitation between two previously implanted MitraClips. (2021) (0)
Novel Antithrombotic Strategies (1998) (0)
HYPERTROPHIC CARDIOMYOPATHY Role of Myocardial Contrast Echocardiography During Nonsurgical Septal Reduction Therapy for Hypertrophic Obstructive Cardiomyopathy (2016) (0)
A CASE OF INTRAMYOCARDIAL DISSECTING HEMATOMA RECOVERED WITH VA-ECMO SUPPORT (2022) (0)
Bleeding Edge Technology: Retroperitoneal Hemorrhage and Its Implications for Transradial Access. (2018) (0)
Erratum: Immature platelet fraction (IPF) determined with an automated method predicts clopidogrel hyporesponsiveness (Journal of Thrombosis and Thrombolysis DOI: 10.1007/s11239-011-0665-7) (2012) (0)
Cautionary tale or exploratory trek - Predicting mortality using the DAPT score. (2020) (0)
THE ROLE OF TRANSCATHETER AORTIC VALVE REPLACEMENT IN LOW-FLOW, LOW-GRADIENT AORTIC STENOSIS: INSIGHTS FROM THE EVOLUT LOW RISK TRIAL (2022) (0)
TCT-522 Long-Term Outcomes with Saphenous Vein Graft versus Native Coronary Artery Intervention in Patients with Coronary Artery Bypass Grafting: Evidence From Meta-analysis and Meta-regression (2018) (0)
Human Basic Fibroblast Growth Factor Induces Angiogenesis in Hen Eggs and Rat Hearts (1999) (0)
TCT CONNECT-351 Percutaneous Interventions for Recurrent Mitral Regurgitation After Surgical Repair: Decision-Making Algorithm and Long-Term Outcomes for MitraClip (2020) (0)
Guest Editors Neal Kleiman And Michael J. Reardon Lend Expertise on Special TAVI Issue (2012) (0)
Aspirin, Heparin, and Other Ancillary Therapies Following Thrombolysis (1992) (0)
Abstract 15708: Does Targeted Low Dose Heparin Negate the Efficacy and Safety of Bivalirudin in Patients Undergoing Percutaneous Coronary Intervention? Insights from a Propensity Score Matched Analysis of the EVENT Registry (2010) (0)
Are we there yet? deciding when it is safe (and wise) to stop clopidogrel after stent implantation. (2014) (0)
TAVI: transcatheter aortic valve implantation. (2011) (0)
Giant Coronary Sinus Complicated by Spontaneous Thrombosis (2022) (0)
TCT-558 Red Cell Distribution Width As A Correlate Of Post-Percutaneous Intervention Bleeds (2012) (0)
Abstract 20183: Intraprocedural C-Arm CT Imaging Identifies Incomplete Stent Frame Expansion in Self-Expanding Aortic Valve Prostheses Associated With Perivalvular Aortic Regurgitation (2014) (0)
An Updated Meta-Analysis on Cerebral Embolic Protection in Patients Undergoing Transcatheter Aortic Valve Intervention Stratified by Baseline Surgical Risk and Device Type (2023) (0)
THE USE OF HEMODYNAMIC SUPPORT IN OCTOGENERIAN PATIENTS DURING HIGH RISK PERCUTANEOUS CORONARY INTERVENTIONS (2014) (0)
16.58 Adenosine tetrofosmin SPECT very early after percutaneous coronary intervention (2001) (0)
The impact of transfusions on mortality after transcatheter or surgical aortic valve replacement. (2020) (0)
Percutaneous transluminal coronary angioplasty in the treatment of patients with unstable angina and acute myocardial infarction (1988) (0)
CHANGES OVER TIME IN QUALITY OF LIFE IN INTERMEDIATE RISK AORTIC STENOSIS PATIENTS UNDERGOING TAVR OR SAVR IN THE SURTAVI TRIAL (2022) (0)
Transcatheter valvular interventions in 2017: some things old, some things new! (2018) (0)
TCT-760 All-Cause Mortality after Surgical or Trans-Catheter Aortic Valve Replacement in Patients with Low-Flow Low-Gradient Aortic Stenosis (2013) (0)
TCT-510 Percutaneous Coronary Intervention Before Transcatheter Aortic Valve Replacement: A Propensity Score–Weighted Analysis (2022) (0)
Abstract 14992: Outcomes of Off-Label Use of Transcatheter Aortic Valve Replacement (TAVR) in the U.S.: Insights From the STS/ACC TVT Registry (2015) (0)
Resistance or resistors? Has Ohm's law come to antiplatelet therapy? (2010) (0)
Trends and Outcomes of Transcatheter Aortic Valve Implantation Among Solid Organ Transplant Recipients. (2020) (0)
Events) Registry Report From the EVENT (Evaluation of Drug Eluting Stents and Ischemic Patients With Chronic Kidney Disease in the Era of Drug-Eluting Stents: A In-Hospital and 1-Year Outcomes Among Percutaneous Coronary Intervention (2011) (0)
LATE TRANSCATHETER HEART VALVE THROMBOSIS WITH SEVERE AORTIC STENOSIS LEADING TO CARDIOGENIC SHOCK: A HEART TEAM APPROACH (2022) (0)
Monster Under the Bed?: Coronary Access After TAVR. (2021) (0)
A STITCH IN TIME SAVES NINE: PROMPT SURGICAL REPAIR OF AORTIC ROOT RUPTURE DURING TRANS-CATHETER AORTIC VALVE REPLACEMENT (2020) (0)
NOW YOU SEE ME NOW YOU DON’T: SUBAORTIC MEMBRANE CAUSING A DIAGNOSTIC DILEMMA (2023) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Neal S. Kleiman?

Neal S. Kleiman is affiliated with the following schools:

Neal S. Kleiman's Academic­Influence.com Rankings

Why Is Neal S. Kleiman Influential?

Neal S. Kleiman's Published Works

Published Works

What Schools Are Affiliated With Neal S. Kleiman?

Neal S. Kleiman's AcademicInfluence.com Rankings